865759-25-7
865759-25-7 structure
- Name: Trelagliptin
- Chemical Name: 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile
- CAS Number: 865759-25-7
- Molecular Formula: C18H20FN5O2
- Molecular Weight: 357.382
- Catalog: Biochemical Inhibitor Proteases DPP-4 inhibitor
- Create Date: 2018-07-14 18:40:27
- Modify Date: 2024-01-02 13:57:12
-
Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.
| Name | 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile |
|---|---|
| Synonyms |
Trelagliptin (USAN)
2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)-4-fluorobenzonitrile Trelagliptin UNII-Q836OWG55H Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluoro- SYR 472 |
| Description | Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). IC50 value:Target: DPP4Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance. |
|---|---|
| Related Catalog | |
| References |
[1]. Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus [2]. Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 519.0±60.0 °C at 760 mmHg |
| Molecular Formula | C18H20FN5O2 |
| Molecular Weight | 357.382 |
| Flash Point | 267.7±32.9 °C |
| Exact Mass | 357.160095 |
| PSA | 97.05000 |
| LogP | 1.88 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.646 |
| Storage condition | -20°C |
| Water Solubility | Practically insoluble (0.034 g/L) (25 ºC) |